Navinci and Lumito initiate pilot project
Navinci and Lumito initiate pilot project – promising initial results from evaluation of combined technology
Navinci and Lumito initiate pilot project – promising initial results from evaluation of combined technology
Navinci is pleased to announce that Dr. Di Peng has been awarded a DDLS Postdoctoral Fellowship 2026, with Navinci as the industrial host
Navinci announces its participation in the European Association for Cancer Research (EACR) 2026 Congress, taking place from June 8–11, 2026 in Budapest, Hungary.
Navinci announces Omni is a multiplex in situ proximity ligation assay with a fluorescent readout, enabling the simultaneous detection of up to 9 protein–protein interactions, post-translational modifications, or single protein targets with high specificity and sensitivity.
Navinci to attend AACR and continue the pre-launch of new multiplex kit
Navinci enters into cross-institutional collaboration for high-throughput spatial interactomics
Navinci to attend NextGen Omics and Spatial Biology US as silver sponsor and pre-launch new multiplex kit
Navinci reports record sales growth of 72% in 2025
Navinci and Vector Labs Highly Commended at CiteAb Awards 2026 for the Innovation Award.
Navinci today announced the appointment of Kjell Ruth as Chief Commercial Officer (CCO).
Navinci has been featured in an article by BioStock highlighting the company’s unique technology and future ambitions.
Professor Joakim Lundeberg, a world-leading expert in molecular biotechnology and spatial biology, has joined Navinci’s Board of Directors.